Use of beta-adrenergic receptor blocking drugs in psychiatry.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000437:Alcoholism / Q000188:drug therapy; D001007:Anxiety / Q000188:drug therapy; D002707:Chlordiazepoxide / Q000627:therapeutic use; D003975:Diazepam / Q000627:therapeutic use; D006801:Humans; D006985:Hyperventilation / Q000188:drug therapy; D001523:Mental Disorders / Q000188:drug therapy*; D010096:Oxprenolol / Q000627:therapeutic use; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D013015:Sotalol / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000188:drug therapy; D013564:Sympathetic Nervous System / Q000187:drug effects; D014202:Tremor / Q000188:drug therapy
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D010096:Oxprenolol; D002707:Chlordiazepoxide; D011433:Propranolol; D013015:Sotalol; D003975:Diazepam